Amneal Pharmaceuticals acquisitions, on the record

Word for word“On December 30, 2021, we entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, “Saol”), a private specialty pharmaceutical company, pursuant to which we agreed to acquire Saol’s baclofen franchise, including Lioresal®, LYVISPAH™, and a pipeline product under development (the “Saol Acquisition”).” 10-K for 2023

Word for word“On November 2, 2021, we entered into a definitive agreement to acquire Puniska Healthcare Pvt. Ltd. (“Puniska”), a privately held manufacturer of parenteral and injectable drugs in India.” 10-K for 2023

Word for word“Kashiv Specialty Pharmaceuticals, LLC On April 2, 2021, the Company and Kashiv Biosciences, LLC (a related party, refer to Note 24. Related Party Transactions ) (“Kashiv”) closed on a transaction for Amneal to acquire a 98% controlling interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), a subsidiary of Kashiv focused on the development of innovative drug delivery platforms, novel 505(b)(2) drugs, and complex generics.” 10-K for 2023

Word for word“Consideration for the Saol Acquisition included approximately $84.7 million, paid at closing with cash on hand, and contingent royalty payments based on annual net sales for certain acquired assets, beginning in 2023.” 10-K for 2024

Word for word“Proceeds from sale of subsidiary 11,994 — — Net cash used in investing activities ( 62,996 ) ( 69,189 ) ( 174,309 ) Cash flows from financing activities: Payments of deferred financing, refinancing costs and debt extinguishment costs ( 71 ) ( 162,415 ) ( 1,663 ) Payments of principal on debt, revolving credit facility, financing leases and other ( 188,918 ) ( 414,080 ) ( 123,272 ) Proceeds from issuance of debt — 217,732 — Borrowings on revolving credit facility 48,000 219,000 85,000 Proceeds from exercise of stock options 1,154 451 662 Employee payroll tax withholding on restricted stock unit vesting ( 7,952 ) ( 2,378 ) ( 3,571 ) Payments of deferred consideration for acquisitions - related party — — ( 44,498 ) Acquisition of redeemable non-controlling interests — — ( 1,722 ) Tax distributions to non-controlling interest ( 19,804 ) ( 70,883 ) ( 17,556 ) Repayment of related party note ( 44,200 ) — — Net cash used in financing activities ( 211,791 ) ( 212,573 ) ( 106,620 ) Effect of foreign exchange rate on cash ( 999 ) 65 ( 5,683 ) Net increase (decrease) in cash, cash equivalents, and restricted cash 19,313 63,880 ( 221,512 ) Cash, cash equivalents, and restricted cash - beginning of period 99,107 35,227 256,739 Cash, cash equivalents, and restricted cash - end of period $ 118,420 $ 99,107 $ 35,227 Cash and cash equivalents - end of period $ 110,552 $ 91,542 $ 25,976 Restricted cash - end of period 7,868 7,565 9,251 Cash, cash equivalents, and restricted cash - end of period $ 118,420 $ 99,107 $ 35,227 The accompanying notes are an integral part of these consolidated financial statements.” 10-K for 2024

Word for word“In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”).” 10-K for 2025